Nanoparticles(NPs) have unique physicochemical properties that are difficult from those of the bulk material. Properties such as small size (< 100nm), relatively high surface-to-volume ratio, quantum dot effect and reactivity, allow a wide range of different applications in modern industry. Nanotechnology is considered as a technology of the future, with a greater potential in biochemical applications. It is becoming increasingly important in nano-diagnostic(medical imaging, biosensors, contrast agents and invitro 'lab-on-a chip'), drug-delivery devices(for gene delivery and targeting drugs) and for treating a variety of human tumors. Researches have developed a novel cancer-targeting nano-particle that can potentially act as a drug-delivery agent and dual imaging agent at the same time. It is well said that " Successful development of targeted cancer therapeutics is vital, as many current chemotherapy regimens lead to severe systemic toxicity due to the fact that the toxic drugs will kill healthy tissue whilst in circulation….". Targeted drugs will hopefully reduce adverse reactions by limiting their action to cancer tissue only. Nanoparticles can easily be functionalized to target specific types and may be promising delivery and imaging in the treatment of cancer. The clinical feasibility of nanoparticle therapeutics will depend on the effectiveness, safety and cost. Nanoparticle capable of site-specific and intracellular delivery combined with optimal RNA-design are needed to maximize the therapeutic efficacy to reduce dosage and non-specific effects. " Nano-scientists should…. Focus their efforts on nano-oncology. So far studies carried out suggest they could make a significant impact in treating various malignancies".
INTRODUCTION
Nanotechnology is the development of engineered device at the atomic, molecular and macromolecular level in nanometer range. Nanoparticles have potential application in medical field including diagnostic and therapeutics. Nanotechnology devices are being developed for early diagnosis of cancer by generating in-vivo sensors to detect location of tumour and early detection of metastatic changes. Advances in nano-technology also proved beneficial in therapeutic field such as drug-discovery, drug-delivery and gene/protein delivery. Nanoparticles can be constructed by various methodology so that effect can be targeted at the desired site. [1] [2] [3] Nanotechnology is the creation of very small particle device and system. This technology takes place at a very minute level. One nanometer = one-billionth of a meter; the width of about 5 atoms. This technology is being developed and designed to interact with cells at a molecular(sub-cellular) level with high degree of functional specificity, thus allowing integration between the device and biological system.Nanoscale devices are 100-10000 times smaller than the human cell. Because of their small size and larger surface area relative to their volume, nano-scale devices can readily interact with biomolecules(enzymes, receptors) on both surface of cell and inside the cell. [4] [5] [6] The use of materials in nano-scale provides more freedom to modify fundamental properties such as solubility, diffusivity, blood circulation t 1/2 ,drug release characteristics, and immunogenicity. These nano-scale agents may provide more effective and/or more convenient route of administration, lower therapeutic toxicity, extend the product life-cycle, and ultimate it reduce the health care costs. [4] [5] As therapeutic delivery system, nano-particle allow targeted delivery and controlled release. For diagnostic applications, nano-particles allow detection of the molecular scale: they help identify abnormalities such as fragments of viruses, precancerous cells, and disease markers that cannot be detected with traditional diagnostics. Nano-particle based imaging contrast agents have also been shown to improve the sensitivity and specificity of magnetic resonance imaging. [7] [8] Advantages of nano-particle based drug delivery system. [6] [7] it improves the solubility of poorly water soluble drugs.
it prolongs the half-life of drug systemic circulation by reducing immunogenicity.
it release drug at a sustained rate or in an environmentally responsive manner and thus decreases the frequency of administration.
delivers drug in a target manner to minimize systemic side-effects.
it can deliver two-or more drug simultaneously for combination therapy to generate synergistic effect and suppress drug resistance.
NANO-PARTICLE BASED THERAPEUTICS AND CLINICAL USE
More than 150 companies are developing nano-sale therapeutics. 24 nanotechnology based therapeutic products have been approved for clinical use. Among these products,liposomal drugs and polymer-drug conjugates are two dominant classes , accounting for more than 80% of the total amount.
Liposomes are spherical lipid vesicles with a bilayered membrane structure composed of natural or synthetic amphiphilic lipid molecules. Liposomes have been widely used as pharmaceutical carriers because 9-11 ----ability to encapsulate both hydrophilic and hydrophilic therapeutic agents with high efficiency.
can protect the encapsulated drugs from undesired effects of external conditions.
can be functionalized with specific ligands that can target specific cells, tissues, and organs .
can be coated with inert and biocompatible polymers such as PEG, thereby prolonging the liposome circulation half-life in-vivo , and can form desired formulations with needed composition, size, surface charge, and other properties. Small-molecule therapeutic agents have two unfavourable properties Short circulation t1/2 , which leads to frequent administration.
Non-site-specific targeting, resulting in undesired systemic side-effects.
The conjugation of small-molecule drugs to polymeric nanocarriers can improve undesirable adverse effects.
Polymer-drug Conjugates10,13
Prolong the in-vivo circulation time from several minutes to several hours.
Reduce the cellular up-take to the endocytic route thereby enhancing the passive delivery of drugs to tissues with leaky blood vesels., such as tumors and atherosclerotic plaques.Many polymers can act as drug delivery carriers. Besides liposomes and polymeric conjugates, other nanoparticle platform includes polymeric nano-particles., micelles., nano-shells., dendrimers, engineered viral nanoparticles., albumin-based nanoparticles.,polysaccharide-based-nano-particle., metallic nano-particles and ceramic nano-particles. 21, 23 Biodegradable polymeric micelles with a size of 10-200nm act as drug delivery nano-carriers with therapeutic potential. Polymeric micelle are formed by self-assembly of block copolymers consisting of two or more polymer chains with different hydrophobicity. These copolymers spontaneously assemble into a core-shell micellar structure in an aqueous environment to minimize the system's free energy.
Specifically, the hydrophobic blocks form the core to minimize their exposure to aqueous surroundings, whereas Hydrophilic blocks form the corona-like shell to stabilize the core through direct contact with water.This micellar structure provides an ideal drug delivery nanocarrier. Its hydrophobic core is capable of carrying pharmaceuticals , especially poorly soluble drugs, with high loading capacity (5-25% weight). Its hydrophilic shell provides a steric protection for micelle, thereby increasing its stability in blood. It also provides functional groups suitable for further micelle modification.
Each polymeric micelle can carry more drugs due to its considerably large size and can release drug in more regulated manner. The encapsulated drugs can be released through surface or by bulk erosion of the biodegradable polymers or by diffusion of drug through polymer matrix or by polymer swelling followed by drug diffusion.
External conditions such as change of pH and temperature can also trigger drug release from polymeric micelles. Polymeric micelles are more stable in blood than liposomes and other surfactant micelles because some amphiphilic copolymers have a considerably lower critical micelle concenteration value.
These polymeric micelle systems can also be used to codeliver two or more drugs with similar or different water solubility for combination therapy or to simultaneously deliver two or more therapeutic modalities such as radiation agents and drugs.
The surface modification of these micelles with ligands such as antibodies, peptides, nucleic acid aptamers, carbohydrates and small molecules can differentially target their delivery and uptake by subset of cells, which will further increase their specificity and efficacy and reduce their systemic toxicity. Usually soft-nanoparticles but also hard-nanoparticles eg metallic NP's,ceramic NP's are also available. 20, 21, 23 .
BIODEGRADABLE POLYMERS
Example of metallic-nanoparticle are iron-oxide, which can be used as passive or targeting agent after being coated with dextran, surfactants, phospholipids, to improve their stability. Gold-NP's have good optical and chemical property and thus show high infra-red phototherapy potential. Aminosilane-coated iron-oxide nanoparticle have been utilized in thermotherapy to treat brain tumor in rat model. These can increase survival time 4.5 fold over control. Ceramic nanoparticle such as silica, titania, alumina are bio-inert and have porous structure. These nanoparticles have been proposed as drug delivery vehicle to carry drugs for various cancer therapies.
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Nano-toxicity and major problems with Nano-particle Delivery are: polymer toxicity; immunogenicity; nonspecific bio-distribution; in-vivo circulation instability; lowdrug carrying capacity; rapid drug release and manufacturing problems. 
CONCLUSION

